Therapeutic areas and Protocols
Cardiology
Active Studies - Cardiology
BaxHTN
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Baxdrostat in participants with uncontrolled hypertension taking two or more medications, including participants with resistant hypertension.
LIBREXIA ACS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Based Study to Demonstrate the Efficacy and Safety of an Oral Factor XIa Inhibitor, Following Recent Acute Coronary Syndrome (ACS)
HERMES
Effects of ziltivekimab versus placebo on morbidity and mortality in patients with chronic heart failure with preserved ejection fraction and systemic inflammation.
LIBREXIA AFL
A Phase 3, randomized, double-blind, double-dummy, parallel-group, active study to evaluate the efficacy and safety of Milvexian, an oral factor XIa Inhibitor, versus apixaban in participants with atrial fibrillation.
Completed Studies - Cardiology
AMETHYST
AMETHYST - D5496C00005
"A Phase 2, multicenter, double-blind, 3-arm, placebo- and active-controlled study to evaluate the efficacy and safety of Verinurad combined with allopurinol in heart failure with preserved ejection fraction."
NODE-303
Multicenter, multinational, open-label study to evaluate the safety of etripamil nasal spray in patients with paroxysmal supraventricular tachycardia. Phase III
AUGUSTUS
CV185316 Open-label, 2x2 factorial, randomized, controlled clinical trial to evaluate the safety of Apixaban compared to a vitamin K antagonist and aspirin compared to aspirin placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention.
MARINER
RIVAROXDVT3002; Phase 3 BAY 59-7939/17261
Evaluation, in patients with medical conditions, of rivaroxaban versus placebo in reducing the risk of venous thromboembolism after hospital discharge
(MARINER)
DAPA HF
DAPA HF – D1699C00001 Study to evaluate the effect of Dapagliflozin on the incidence of worsening heart failure or cardiovascular mortality in patients with chronic heart failure with reduced ejection fraction
VOYAGER PAD
BAY 59-7939/17454 Phase III, randomized, placebo-controlled, double-blind, international, multicenter study investigating the efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in patients with symptomatic peripheral arterial disease undergoing lower extremity revascularization procedures.
Cardiovascular
Active Studies - Cardiovascular
TRIUMPH
J1I-MC-GZBO
“Estudio en Fase III, aleatorizado, doble ciego, controlado con placebo, basado en eventos para investigar el efecto de la retatrutida sobre la incidencia de los eventos adversos cardiovasculares mayores y el deterioro de la función renal en participantes con un índice de masa corporal >=27 kg/m2 y ateroesclerosis cardiovascular y/o nefropatía crónica."
BalanceD-HF
"Estudio de fase III, aleatorizado, doble ciego para evaluar el efecto de balcinrenona/dapagliflozina, en comparación con dapagliflozina, sobre el riesgo de episodios de insuficiencia cardíaca y muerte cardiovascular en pacientes con insuficiencia cardíaca y deterioro de la función renal (BalanceD-HF)"
ACCLAIM-Lp(a) – J3L-MC-EZEF
“Un estudio de Fase 3, randomizado, doble ciego, controlado con placebo para investigar el efecto de Lepodisirán en la reducción de eventos adversos cardiovasculares mayores en adultos con lipoproteína(a) elevada, que presentan enfermedad cardiovascular aterosclerótica establecida o corren el riesgo de presentar el primer evento cardiovascular - ACCLAIM-Lp(a)”
Completed Studies - Cardiovascular
SYNCHRONIZE
A Phase III, Randomized, Double-Blind, Parallel-Group, Event-Driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared to Placebo in Participants With Overweight or Obesity
SURMOUNT – Obesity
A Phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of Tirzepatide in reducing morbidity and mortality in adults with obesity. This study will investigate the effect of tirzepatide on reducing morbidity and mortality in adults living with obesity and will provide additional evidence of the potential clinical benefits of tirzepatide in this population.
ZEUS
Research study to see how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease, and inflammation.
ESPERION
1002-043 - Esperion
"Randomized, double-blind, placebo-controlled study to evaluate the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with cardiovascular disease or at high risk of developing it, who do not tolerate statins"
Dermatology
Active Studies - Dermatology
1368-0098
Randomized, double-blind, placebo-controlled, phase IIb/phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa
Completed Studies - Dermatology
PSO3001
Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of JNJ-77242113 in the treatment of participants with moderate to severe plaque psoriasis, with randomized withdrawal and retreatment
INCB 18424-319
Phase III, double-blind, randomized, vehicle-controlled study to evaluate the efficacy and safety of ruxolitinib cream in participants with prurigo nodularis; Topical evaluation of ruxolitinib in nodular prurigo (TRuE-PN1)
Diabetes
Active Studies - Diabetes
There are no active studies at this time
Completed Studies - Diabetes
ACHIEVE-3
J2A-MC-GZGU A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Oral LY3502970 Once Daily Compared to Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
MK 0431-845
MK0431-845
Phase III, multicenter, randomized, double-blind, placebo-controlled clinical study to study the efficacy and safety of continued administration of sitagliptin compared to withdrawal of sitagliptin during initiation and titration of insulin glargine (LANTUS®) in participants with type 2 diabetes mellitus
MK 8835-001
MK 8835-001
“Phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus with stage 3 chronic kidney disease, “whose glycemic control is inadequate with basic antihyperglycemic treatment”
DIA 4003
Protocol 28431754DIA4003
“Randomized, multicenter, double-blind, parallel, placebo-controlled study of the effects of canagliflozin on renal endpoints in adult subjects with type 2 diabetes mellitus.”
HARMONY
LPG 116174
“Long-term, randomized, double-blind, placebo-controlled study to determine the effect of albiglutide added to standard blood glucose-lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus.”
VERTIS
MK-8835-004-01/ B1521021
“Randomized, double-blind, placebo-controlled, parallel-group study to evaluate cardiovascular outcomes after treatment with ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus and established vascular disease,” the cv study "Vertis."
ABBVIE
Estudio aleatorizado, multipaís, multicéntrico, a doble ciego, paralelo y controlado con placebo sobre los efectos de atrasentan en resultados renales de sujetos con diabetes tipo 2 y nefropatía. SONAR: estudio de nefropatía diabética con atrasentan
SCORED
EFC14875 – SCORED - Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to demonstrate the effects of sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes, cardiovascular risk factors and moderate renal failure
Endocrinology
Estudios Activos - Endocrinología
MULBERRY
ALXN1850-HPP-305
“Fase 3, Aleatorizado, Doble Ciego, Controlado con Placebo,
Estudio multicéntrico para evaluar la eficacia y la seguridad de ALXN1850 frente a la administración de placebo Subcutáneamente en participantes pediátricos sin tratamiento previo (de 2 a < 12 años de edad) con Hipofosfatasia (HPP)”
HICKORY
ALXN1850-HPP-301
“Un estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico para evaluar la eficacia y la seguridad de ALXN1850 (Fosfatasa Alcalina Recombinante) administrada por vía subcutánea en participantes adolescentes (de 12 a < 18 años de edad) y adultos con hipofosfatasia que no han sido tratados previamente con Asfotase Alfa”
Estudios Finalizados - Endocrinología
No hay estudios finalizados en este momento
Gastroenterology
Estudios Activos - Gastroenterología
MK 7240-001
Programa de fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de MK-7240 en participantes con colitis ulcerosa activa de moderada a grave
LIBERTY
“Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad del tratamiento con dupilumab en pacientes con colitis ulcerosa activa de moderada a severa con fenotipo eosinofílico”
ASTRO
Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of subcutaneous induction treatment with Guselkumab in participants with moderately to severely active ulcerative colitis.
Completed Studies - Gastroenterology
AMG 592 20210210
A Phase 2 Long-Term Extension (LTE) Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
DUET-UC
Estudio de fase 2b aleatorizado, doble ciego, con control activo, de grupos paralelos y multicéntrico para evaluar la eficacia y la seguridad de la terapia combinada de inducción y mantenimiento con guselkumab y golimumab en participantes con colitis ulcerosa activa de moderada a grave.
CC-93538-EE-02
“Estudio de extensión de fase 3, multicéntrico, multinacional, abierto, para evaluar la seguridad a largo plazo de CC-93538 en sujetos adultos y adolescentes con esofagitis eosinifílica”
AMG592 20170104
A Phase 2, dose-finding, randomized, double-blind, placebo-controlled, multicenter study. To evaluate the safety and efficacy of Efavaleukin alfa in induction therapy in participants with moderately to severely active ulcerative colitis
QUASAR
Ulcerative colitis
RLM-MD-04
RLM-MD-04
“52-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis”
RLM-MD-03
RLM-MD-03
“46-week, double-blind, placebo-controlled, phase 3 study, with a 6-week randomized drug withdrawal period, to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis”
Gynecology
Active Studies - Gynecology
There are no active studies at this time
Completed Studies - Gynecology
ESTETRA
MIT-Do001-C301: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort I Study)
Hepatology
Active Studies - Hepatology
K-001-201
"Estudio de fase 2, multicéntrico, controlado con placebo, aleatorizado, doble ciego, de 48 semanas para evaluar la eficacia y seguridad de la terapia combinada de K-877-ER y CSG452 en pacientes con esteatohepatitis no alcohólica no cirrótica (NASH) con fibrosis hepática"
Completed Studies - Hepatology
FORTUNA
Phase IIb/III, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis.
Infectology
Active Studies - Infectology
RECLAIM
“Un estudio multicéntrico, aleatorizado, doble ciego de Fase 3 para evaluar la seguridad y eficacia de contezolida acefosamil y contezolida en comparación con linezolida administrado por vía intravenosa y oral a adultos con infecciones moderadas o severas del pie diabético”
ENANTA
Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938 in non-hospitalized adults with acute Respiratory Syncytial Virus infection and at high risk of complications.
Completed Studies - Infectology
VOLITION
A study to evaluate the efficacy, safety, participant choice, and preference of a once-daily oral regimen or a bimonthly long-acting injectable regimen for the treatment of HIV-1 in adults not previously taking antiretroviral therapy.
SUNRISE-3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19.
SCORPIO-HR
A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared to Placebo in Non-Hospitalized Participants With COVID-19
BANNER
Estudio abierto, de fase 2a, multicéntrico, aleatorizado, de dos partes, con diseño adaptativo, para evaluar el efecto antiviral, la seguridad y la tolerabilidad de GSK3810109A, un anticuerpo monoclonal humano ampliamente neutralizante específico del VIH-1 en adultos infectados por el VIH-1 sin tratamiento previo con antirretrovirales.
TACKLE
"Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para determinar la seguridad y eficacia de AZD7442 para el tratamiento de COVID-19 en adultos no hospitalizados"
Lipids
Active Studies - Lipids
There are no active studies at this time
Completed Studies - Lipids
PROMINENT
“PROMINENT Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes”
Nephrology
Active Studies - Nephrology
BAXDUO
D6972C00003
"Un estudio de fase III, aleatorizado, doble ciego y controlado de forma activa para evaluar la eficacia, seguridad y tolerabilidad de baxdrostat en combinación con dapagliflozina en comparación con dapagliflozina sola sobre la progresión de la enfermedad renal crónica (ERC) en participantes con ERC y presión arterial alta"
BGB-3111-309
BGB-3111-309: un estudio de fase 3, multicéntrico, aleatorizado, con control activo y abierto para Evaluar la eficacia y seguridad de zanubrutinib en pacientes con membrana primaria Nefropatía. Protocolo de estudio, Versión de enero de 2022.
TRANSCEND-T2D-3
“Estudio en Fase III, aleatorizado, multicéntrico y doble ciego para investigar la eficacia y seguridad de retatrutida administrada una vez a la semana en comparación con placebo en participantes adultos con diabetes tipo 2, insuficiencia renal moderada o grave con control glucémico inadecuado en la insulina basal con o sin metformina y/o inhibidor de SGLT2 (TRANSCEND-T2D-3).”
NN9388-7700
Eficacia y seguridad de cagrilintida s.c. coadministrada. 2,4 mg en combinación con semaglutida s.c. 2,4 mg (CagriSema s.c. 2,4 mg/2,4 mg) una vez a la semana en comparación con semaglutida, cagrilinitida y placebo en personas con enfermedad renal crónica y diabetes tipo 2
ZENITH
Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria
Completed Studies - Nephrology
ZENITH HP /D4325C00007
Study for the Identification and Characterization of Patients with Chronic Kidney Disease and Proteinuria.
CR845-310302 / KICK 2/CARA
Patients with Advanced Chronic Kidney Disease with Moderate to Severe Pruritus and not on Dialysis
CR845-310302 2048/0010
STABILIZE
To evaluate the effect of sodium zirconium cyclosilicate on the progression of chronic kidney disease (CKD) in participants with CKD and hyperkalemia or at risk of hyperkalemia (STABILIZE-CKD)
BI 1378-0005
Randomized, double-blind, placebo-controlled, twelve parallel group study to investigate the efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetes and non-diabetic chronic kidney disease
6 + 5
FLAIR
Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multi-Dose Study of AZD5718 in Participants With Chronic Proteinuric Kidney Disease
Pulmonology
Active Studies - Pulmonology
TANGO
Un ensayo de 52 semanas, aleatorizado, doble ciego, multicéntrico, de grupos paralelos de 2 brazos que evalúa la eficacia y seguridad del inhalador de polvo seco (DPI) CHF6001 (dosis diaria total 3200 ug) como complemento al corticosteroide inhalado de dosis media o alta de mantenimiento en combinación con agonistas ß2 de acción prolongada en sujetos con asma no controlada
GB43374 OLE – ALNASA
Phase III multicenter open-label extension (OLE) study to evaluate the long-term safety and efficacy of astegolimab in combination with standard of care (SOC),
DOMINICA
Estudio de fase 3 de eficacia y seguridad de benralizumab en pacientes pediátricos con asma eosinofílica grave, tiempo hasta la primera exacerbación del asma, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo
CALM Bellus
A Phase 3, 12-Week, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study
of BLU-5937 in Adult Participants With Refractory or Unexplained Chronic Cough (RCC)
(CALM-1)
Pillar – CLI-06001AA1-05
A 52-week, placebo- and active-controlled (roflumilast, Daliresp® 500 µg) study to evaluate the efficacy and safety of two doses of CHF6001 DPI (tanimilast) as an adjunct to triple maintenance therapy in subjects with COPD and chronic bronchitis.
TRITON
Double-blind, multinational, multicenter, randomized, placebo-controlled, three-way crossover study to evaluate the effect of a triple combination of beclometasone dipropionate and formoterol fumarate plus glycopyrronium (CHF5993) and a double combination of beclometasone dipropionate plus formoterol fumarate formoterol (CHF 1535) Both administered via pMDI in pulmonary hyperinflation and exercise endurance time in subjects with chronic obstructive pulmonary disease (COPD)
Completed Studies - Pulmonology
EXHALE 2 ARETEIA
AR-DEX-22-01
Un estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad del dexpramipexol administrado por vía oral durante 52 semanas en participantes con asma eosinofílica grave (EXHALE-2)
ALIENTO
Phase III multicenter open-label extension (OLE) study to evaluate the long-term safety and efficacy of astegolimab in combination with standard of care (SOC),
PILASTER
52-Week Placebo-Controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as an Adjunct to Triple Maintenance Therapy in Subjects With COPD and Chronic Bronchitis
ASPEN INS1007-301
The primary objective of this study is to evaluate the effect of brensocatib at doses of 10 mg and 25 mg compared to placebo on the rate of pulmonary exacerbations (PE) during the 52-week treatment period.
Oncology
Active Studies - Oncology
ZINNIA
20210031
“Un estudio doble ciego, aleatorizado para evaluar la eficacia, la seguridad y la inmunogenia de ABP 206 en comparación con OPDIVO® (Nivolumab) en sujetos con melanoma irresecable o metastásico sin exposición previa al tratamiento”
Completed Studies - Oncology
VERBENA
A randomized, double-blind study to compare the pharmacokinetics, between ABP 206 and Nivolumab (Opdivo®) in subjects with stage III or IV melanoma resected in the adjuvant setting.
TROPION 02
Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients With First-Line Inoperable or Metastatic Locally Recurrent Triple-Negative Breast Cancer Who Are Not Candidates for Inhibitor Therapy PD1/PD-L1 (TROPION Mama02)
lidERA/TRIO045
Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared to Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
TROPION 01
Estudio de fase 3, abierto, aleatorizado, de Dato-DXd frente a la elección del investigador de quimioterapia en participantes con cáncer de mama irresecable o con receptor hormonal metastásico positivo, HER2 negativo que han sido tratados con una o dos líneas previas de quimioterapia sistémica (TROPION Mama01)
213400
“Phase 3, randomized, double-blind, placebo-controlled study,
multicenter to compare niraparib plus pembrolizumab versus placebo plus
pembrolizumab as maintenance treatment in participants whose disease
remained stable or responded to first-line platinum-based chemotherapy
with pembrolizumab against stage IIIB or non-small cell lung cancer
IV”
AMEERA – 5
Estudio de fase 3, aleatorizado, multicéntrico, doble ciego de amcenestrant (SAR439859) más palbociclib en comparación con letrozol más palbociclib para el tratamiento de pacientes con cáncer de mama RE(+), HER2(–) que no han recibido tratamiento antineoplásico sistémico previo para la enfermedad avanzada
CUSA
Phase 3, Randomized, Double Blind, Active
and Placebo Controlled Study on the Use of CUSA-081 for Dysfunctional Central Venous Access
Devices [CVAD]
Pediatría
Estudios Activos - Pediatría
LIBELULA
Debio 4326 HAB97073
"Estudio Fase III, multicéntrico, abierto, de un solo brazo; sobre eficacia, seguridad y farmacogenética de Debio 4326, una formulación de liberación prolongada de 70mg de acetato de triptorelina, en participantes pediátricos que reciben tratamiento liberador de gonadotropina- Terapia de agonía hormonal para la pubertad precoz central."
Estudios Finalizados - Pediatría
No hay estudios finalizados en este momento
Rheumatology
Active Studies - Rheumatology
MK 6194-006
"Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de MK-6194 en participantes adultos con lupus eritematoso sistémico."
APATURA
DRI17821
Un estudio de fase 2, aleatorizado, doble ciego, controlado con placebo, de rango de dosis, eficacia y seguridad de SAR441566 más metotrexato en adultos con artritis reumatoide de moderada a grave.
EMERALD
"Un estudio de extensión a largo plazo, multicéntrico, aleatorizado, a ciegas, de fase 3 para evaluar la Seguridad y eficacia de BIIB059 en participantes adultos con lupus eritematoso sistémico (LES) activo"
WILLOW LTE MS200569_0048
Un estudio de fase II, doble ciego, de dosis variable, paralelo y de extensión a largo plazo para evaluar la seguridad y la eficacia de Enpatoran en participantes con lupus eritematoso cutáneo subagudo, lupus eritematoso discoide y/o lupus eritematoso sistémico que han completado el tratamiento del estudio WILLOW (MS200569_0003)
AMETHYST
230LE301, Part A (Phase 2)/ Part B (Phase 3) Randomized, double-blind, placebo
Multicenter controlled study to evaluate the efficacy and safety of BIIB059 in participants with subacute cutaneous lupus erythematosus and/or chronic cutaneous lupus erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy
(AMETHYST)
TOPAZ
The primary objective of this study is to demonstrate the efficacy of BIIB059 compared to placebo in participants with active systemic lupus erythematosus (SLE), who are receiving lupus standard of care (SOC) treatment to reduce disease activity.
Completed Studies - Rheumatology
JASMINE 80202135SLE2001
Phase 2, multicenter, randomized, double-blind, placebo-controlled study of nipocalimab in subjects with active systemic lupus erythematosus (SLE).
BI 1366-0031
”Estudio de Fase II, aleatorizado, controlado con placebo, doble ciego, de grupos paralelos, para evaluar la eficacia y la seguridad de, al menos, 48 semanas de tratamiento con BI 685509 oral en adultos con esclerosis sistémica progresiva”
MARS-17
Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis (MARS-17) de GSK3858279 en participantes adultos con dolor moderado a severo ocasionado por artrosis de rodilla.
WILLOW
“Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, de determinación de dosis, de diseño paralelo y adaptativo para evaluar la eficacia y seguridad de enpatoran en participantes que reciben un tratamiento estándar para el lupus eritematoso sistémico y el lupus eritematoso cutáneo (lupus eritematoso cutáneo subagudo y/o lupus eritematoso discoide)”
Our Professionals
Authorities
Doctors
Internal Medicine and diabetes
Nutrition
Ophthalmology
Nephrology
Infectology
Dermatology
Pulmonology
Hematology
Rheumatology
Administrative and technical area
Clinical Trial Coordination Assistant
Vallerga, Florencia
Secretaría
Paula Cordoba
Regulatory - Start Up
Executive Area
Infrastructure
Facilities
- 450 square meters
- 10 Offices
- Box for sample extraction
- Box for ECG performance
- Wardrobe for patients
- Pharmacy with security code, alarm and cold chain
- Calibrated thermometers
- Lockable storage location for files and medical records
- Storage space with security code for returned medication.
- Monitoring room
- Breakfast area for patients
- Protected cardio space
Technology
- Fully computerized center
- Protected digital information
- 24 hour fax with direct line
- Printer with scanner on each floor
- Generator set to ensure cold chain in pharmacy
- Wifi
- 24 hour monitoring
Equipment
- Refrigerators and freezers with calibrated thermometers
- Laminar flow hood Blood pressure monitors
- Roma scales
- 2 Centrifuges
- Incubator
- Electrocardiograph
- Spirometer
- Defibrillator
- Cabinet with basket for pathological waste and periodic withdrawals by Environmental Systems
Our Sponsors
